Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Ruxolitinib

1 Open Trial

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCBMT1760

    03/15/2018

    A Phase III Randomized Open-Label Multi-Center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease after Allogenic Stem Cell Transplantation (REACH 3)


    Print this page for your doctor